Business Daily Folgen

Should the collection of vast genetic databases be dominated by private companies such as 23andMe or Ancestry.com?In the second of two programmes looking at the businesses riding high on the boom in home DNA testing kits, Manuela Saragosa looks at how the enormous head start these companies have over public sector DNA research initiatives may be skewing medical research. Will the profit motive drive these companies to wall off their databases, and give access only to pharmaceutical companies capable of developing lucrative new drugs that mainly benefit the predominately wealthy, white customers who send in their DNA samples in the first place?The programme features interviews with Kathy Hibbs of 23andMe, Mark Caulfield of Genomics England, and Kayte Spector-Bagdady of the University of Michigan Medical School.Producer: Laurence Knight(Picture: Woman's cheek being swabbed; Credit: AndreyPopov/Getty Images)

What can you really learn about your heritage from a home DNA testing kit? We hear from Bill and Ylva Wires, a couple in Berlin who used DNA testing kits to find out more about their ancestors. Manuela Saragosa speaks to Rafi Mendelsohn of MyHeritage.com - one major company in this field - and Kristen V Brown who covers genetics stories for Bloomberg.Producer: Laurence Knight(Photo: Old family photos, Credit: Getty Images)

The story of Theranos, a company that falsely claimed it could perform a full range of medical tests using just a tiny blood sample drawn by pricking your finger. Manuela Saragosa speaks to John Carreyrou, an investigative reporter with the Wall Street Journal and author of a book on the case, Bad Blood. Plus Silicon Valley venture capitalist Hemant Taneja explains why investors need to be more cautious.(Photo: Blood samples, Credit: Getty Images)